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Abstract: Background: The prevalence of diabetes is on the increase in the UK and worldwide,
partly due to unhealthy lifestyles, including poor dietary regimes. Patients with diabetes and other
co-morbidities such as stroke, which may affect swallowing ability and lead to malnutrition, could
benefit from enteral nutrition, including the standard formula (SF) and diabetes-specific formulas
(DSF). However, enteral nutrition presents its challenges due to its effect on glycaemic control and
lipid profile. Aim: The aim of this review was to evaluate the effectiveness of diabetes-specific enteral
nutrition formula versus SF in managing cardiometabolic parameters in patients with type 2 diabetes.
Method: This review was conducted in accordance with the preferred reporting items for systematic
reviews and meta-analyses. Three databases (Pubmed, EMBASE, PSYCInfo) and Google scholar were
searched for relevant articles from inception to 2 January 2019 based on Population, Intervention,
Comparator, Outcomes and Study designs (PICOS) framework. Key words, Medical Subject Heading
(MeSH) terms, and Boolean operators (AND/OR) formed part of the search strategy. Articles were
evaluated for quality and risks of bias. Results: Fourteen articles were included in the systematic
review and five articles were selected for the meta-analysis. Based on the findings of the review and
meta-analysis, two distinct areas were evident: the effect of DSF on blood glucose parameters and the
effect of DSF on lipid profile. All fourteen studies included in the systematic review showed that
DSF was effective in lowering blood glucose parameters in patients with type 2 diabetes compared
with SF. The results of the meta-analysis confirmed the findings of the systematic review with respect
to the fasting blood glucose, which was significantly lower (p = 0.01) in the DSF group compared
to SF, with a mean difference of −1.15 (95% CI −2.07, −0.23) and glycated haemoglobin, which was
significantly lower (p = 0.005) in the DSF group compared to the SF group following meta-analysis
and sensitivity analysis. However, in relation to the sensitivity analysis for the fasting blood glucose,
differences were not significant between the two groups when some of the studies were removed.
Based on the systematic review, the outcomes of the studies selected to evaluate the effect of DSF
on lipid profile were variable. Following the meta-analysis, no significant differences (p > 0.05)
were found between the DSF and SF groups with respect to total cholesterol, LDL cholesterol and
triglyceride. The level of the HDL cholesterol was significantly higher (p = 0.04) in the DSF group
compared to the SF group after the intervention, with a mean difference of 0.09 (95% CI, 0.00, 0.18),
although this was not consistent based on the sensitivity analysis. The presence of low glycaemic
index (GI) carbohydrate, the lower amount of carbohydrate and the higher protein, the presence of
mono-unsaturated fatty acids and the different amounts and types of fibre in the DSF compared with
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SF may be responsible for the observed differences in cardiometabolic parameters in both groups.
Conclusion: The results provide evidence to suggest that DSF is effective in controlling fasting blood
glucose and glycated haemoglobin and in increasing HDL cholesterol, but has no significant effect on
other lipid parameters. However, our confidence in these findings would be increased by additional
data from further studies.
Keywords: diabetes specific formula; standard formula; type 2 diabetes; enteral nutrition; enteral
tube feeding; lipids; fasting blood glucose; glycated haemoglobin
1. Introduction
Diabetes is a metabolic condition which is characterised by chronic hyperglycaemia and is caused
by a range of factors including genetic inheritance and environmental influences [1]. The prevalence of
diabetes is on the increase in the UK and worldwide, partly due to the changes in lifestyle, including
lack of physical activity and unhealthy diets, which lead to overweight and obesity [2–5]. In addition,
improvements in technology and the greater awareness of the condition have meant that diabetes is
now better detected and more people are engaging in screening programmes. About 90% of patients
with diabetes are diagnosed with type 2 diabetes [6–8]. The impact of diabetes on the people living
with the condition can be profound in terms of morbidity and mortality, as well as a cost burden to the
National Health Service (NHS). Individuals with diabetes are more likely to be admitted to hospital
and it can have a significant effect on the quality of life of patients [9,10]. Diabetes is a major risk
factor for kidney dysfunction, lower limb amputations, retinopathy, cardiovascular disease and other
co-morbidities such as stroke, which can lead to swallowing problems and malnutrition. Based on these
issues, diabetes continues to be a major public health concern in the UK and globally, and strategies
for managing the condition continue to evolve. Often, management relies on lifestyle modifications
such as increased physical activity levels and the use of dietary interventions in order to prevent the
onset of type 2 diabetes and ultimately reduce the possibility of diabetic complications [11]. However,
in patients who are sedentary and immobile, the use of physical activity as a strategy for managing the
condition is sometimes impracticable.
Therefore, individuals with diabetes and other conditions, such as stroke, which could affect mobility
and swallowing ability, may benefit from enteral nutrition such as oral nutrition supplements and the
use of a nasogastric feeding tube (for short-term feeding) or a percutaneous endoscopic gastrostomy
tube for long-term intervention to deliver enteral feeds and formulas [12]. Usually, these individuals
have functional guts and the essence is to provide adequate nutrition, hydration and medication to these
patients in order to improve their nutritional status and clinical outcomes, including quality of life.
Why it is important to do this review:
The current review focuses mainly on patients with type 2 diabetes from a range of backgrounds,
including those attending diabetes centre/outpatient diabetic clinics, rehabilitation departments,
ambulatory patients, nursing homes and long-term care facilities, and intensive care units. Patients
with diabetes are at a greater risk of developing stroke, peripheral vascular disease, renal impairment
and dementia compared with those without the condition due to chronic hyperglycaemia [13].
The long-term complications of diabetes, including its co-morbidities, have implications for the length
of hospital stay. Thus, while the average length of hospital stay in patients with diabetes as the primary
diagnosis has been estimated to be 4.3 days, it is 8 days in patients with additional diagnoses and 3.1
days in all hospitalisations [14]. The use of enteral feeding in patients with diabetes can present a
range of challenges in the control of blood glucose levels and other cardiometabolic parameters [15].
These parameters, including lipid profile, such as total cholesterol, high density lipoprotein cholesterol,
low density lipoprotein cholesterol and triglyceride, are important biomarkers in patients with type 2
diabetes as they have implications for insulin resistance and cardiovascular mortality.
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In patients with diabetes who are on enteral nutrition, the enteral feeds provided can be in the
form of either Standard Formulas (SF) or Diabetes Specific Formulas (DSF). Enteral feeding formulas
have a tendency to promote hyperglycaemia and insulinemic responses in patients with diabetes and
in healthy subjects [16,17]. In addition, the effect of enteral nutrition on blood glucose parameters may
be due to the fact that continuous enteral feeding is a source of continuous supply of glucose, providing
10–20 g of carbohydrates per hour, which is not the same during normal eating [15]. The absence
of the normal postprandial glucose peak in patients with diabetes on enteral nutrition makes the
management of hyperglycaemia difficult [15]. On the other hand, the effect of different types and
amounts of fibre and mono-unsaturated fatty acids in various enteral feeds may influence lipid profile
and other cardiometabolic parameters such as fasting blood glucose and glycated haemoglobin in
patients with type 2 diabetes [18]. The role of the different enteral feeding formulas such as SF and
DSF and their impact on cardiometabolic parameters in patients with diabetes continues to generate
interest and controversy, and there appears to be no consensus among researchers on the most effective
management strategy for these patients.
DSFs usually contain carbohydrates with low GI such as fructose and large amounts of
monounsaturated fatty acids in varying amounts, which have effect on glycaemic control [17–20].
On the other hand, SFs are often high in carbohydrate and contain only low to moderate levels of lipids
and do not have dietetic fibre [17].
Previous reviews on the use of enteral nutrition in patients with diabetes [16,17,21–23] either
lacked consensus in the recommendations, were based only on glycaemic control or did not involve
meta-analysis. In addition, concerns remain with the use of DSF in terms of the safety and tolerance of
relatively high levels of fat and fructose with respect to lipid metabolism and lactic acidosis, despite its
advantage in improving blood glucose compared with SFs [16,19]. Therefore, this review provides a
quantitative assessment of the relative effectiveness of DSF compared with SF.
Aim: The aim was to evaluate the effectiveness of diabetes specific enteral nutrition formula
versus SF in managing cardiometabolic parameters in patients with type 2 diabetes.
2. Methods
This study was conducted in accordance with the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) [24].
2.1. Types of Studies and Participants
Only randomised controlled studies were included in this review and participants were patients
with type 2 diabetes.
Inclusion and Exclusion Criteria.
The criteria for considering studies for the review are outlined in Table 1.
Table 1. Criteria for considering studies for the review based on the Population, Intervention, Comparator,
Outcomes and Study designs (PICOS) Structure.
Inclusion Criteria Exclusion Criteria
Population
Patients with type 2 diabetes and on
enteral nutrition irrespective of type
of feeding tube.
Patients with type 1 diabetes.
Pregnant women with gestational diabetes.
Healthy individuals without diabetes on enteral nutrition.
Patients with diabetes on parenteral nutrition and
parenteral plus enteral nutrition.
Studies involving animals
Intervention
Diabetes specific formulas
Parenteral nutrition, parenteral plus enteral nutrition.(Oral nutrition supplement or
enteral tube feeding)
Comparator Standard formulas (Oral nutritionsupplement or enteral tube feeding) Parenteral nutrition and parenteral plus enteral nutrition.
Outcomes Cardiometabolic parameters Qualitative outcomes such as patient feelings.
Study Design: Randomised Controlled Trials Letters, comments, reviews, qualitative studies
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2.2. Type of Intervention
The intervention for this review was based on diabetes-specific enteral formula, irrespective of
the type of feeding tube, mode and rate of delivery of the enteral feed and clinical settings.
2.3. Types of Outcome Measures
The following were the outcome measures of interest;
• Blood glucose parameters—Fasting blood glucose and glycated haemoglobin.
• Lipid profile: Total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein
(HDL) cholesterol and triglycerides.
2.4. Search Strategy
Databases encompassing Pubmed, EMBASE, PSYCInfo and Google scholar were searched for
relevant articles based on the Population (Patients with diabetes), Intervention (Diabetes Specific
Formula), Comparator (Standard enteral formulas), Outcomes (outcome measures) and Study designs
(Randomised controlled studies)—PICOS framework (Table 2) [25]. The use of key words, truncation
symbols, Medical Subject Heading (MeSH) terms and Boolean operators (AND/OR) formed part of the
search strategy. Searches were conducted from the date of inception of databases until 2 January 2019.
The screening of studies and the evaluation of their eligibility and inclusion were in line with
PRISMA [24] guidelines (Figure 1). These procedures were conducted by five researchers (OO, SMW,
TT, RC, X-HW) and differences were resolved through consensus.
Table 2. Search method for identification of studies.
Patient/Population Intervention Comparator Study Designs CombiningSearch Terms
Patients with type
2 diabetes
Diabetes specific
formulas
Standard
formulas
Randomised
Controlled Trial
Type 2 diabetes OR
type 2 diabetes
mellitus OR
Diabetes
complications OR
diabetes mellitus,
type 2
Diabetes specific
formula OR Diabetes
specific form* OR
Enteral nutrition OR
Enteral* OR Enteral
feed OR Enteral feed*
OR Enteral form* OR
Diabetes formula OR
tube feeding OR
enteral feeding
Randomised
Controlled Trial OR
Randomized
Controlled Trial OR
Randomized
Controlled study OR
RCT OR Randomized*
OR controlled clinical
trial OR placebo OR
randomly OR trial OR
groups
Column 1 AND
Column 2 AND
Column 3
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Figure 1. PRISMA flow chart on selection and inclusion of studies.
2.5. Data Extraction
All the articles from different databases were exported to ENDNote (Analytics, Philadelphia, PA,
USA) for de-duplication. Data extraction was carried out by one researcher (OO) and cross-checked by
the other four researchers (SMW, TT, RC, X-HW).
2.6. Assessment of Risk of Bias and Evaluation of Quality
A critical appraisal skills programme (CASP) tool was used to appraise the quality of the articles [26].
In addition, the researchers carried out an assessment of the risk of bias using the domain-based tool
(random sequence generation, allocation concealment, blinding of participants, personnel and outcome
assessment, reporting bias and selective reporting) to evaluate the studies included [27].
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2.7. Statistical Analysis
Articles that met the inclusion criteria for meta-analysis were exported to RevMan (Review
Manager, 5.3) [28] for data analysis. Therefore, cross-over studies and other studies which presented
with difficulty in extracting suitable data were excluded from the meta-analysis. The data analysis
included both meta-analysis and sensitivity analysis, the latter being conducted to test the consistency
of the effect of DSFs on the different cardiometabolic paramters. The random effects model was used
for the parameters of interest due to the high level of heterogeneity measured by the statistic I2 with
values ranging from 34% to 100%. A p value of 0.10 was used to determine the statistical significance
of heterogeneity.
2.8. Effect Size
A forest plot was used to present the results of the meta-analysis and statistical significance for
the overall effect of the intervention was determined by a p value of <0.05.
3. Results
3.1. Data Inclusion Decisions
Fasting blood glucose in the studies included was measured after overnight fasting, using standard
measuring instruments. This is the standard method of measuring fasting blood glucose: the blood
glucose concentrations were expressed as Means. However, the studies by Pohl et al. [29,30] were
expressed as median and interquartile ranges and these were converted to means and standard
deviations [27]. Fourteen studies were included in the systematic review (Table 3) while only five
studies [29–33] were selected for the meta-analysis (Table 4).
Nutrients 2019, 11, 1905 7 of 18
Table 3. Characteristics of the articles included in this review (n = 14).
Citation Country Length ofStudy Study Type/Design
Sample
Size/Description Age (Years)
Type of Enteral
Formula/Feeding Method
Duration of
Diabetes
(Years)
Study Results/Conclusion
Ceriello et al.
[18] Netherlands 24 h
Randomized, controlled,
double-blind, cross-over n = 11
Mean ± SEM
The DSF had 1 kcal/mL and
low GI and/or slowly
digestible CHO. The SF was
isocaloric fibre containing
formula.
Mean ± SEM Administration of DSFlowered glucose profiles.
67.2 ± 1.3 Bolus Feeding 6.6 ± 1.4 years
Using DSF resulted in
significantly lower 24 h and
postprandial glucose profiles
than fibre-containing SF after
bolus administration.
Buranapin et al.
[20] Thailand 180 min
Single centre, prospective,
randomized, double blind,
cross-over study. n = 30
Mean ± SD
55% CHO, 15% protein, 30%
fat for DSF and SF. However,
DSF substituted sucrose for
combination of fructose,
polydextrose and FOS. Bolus
Feeding
More than 6
months.
DSF resulted in significantly
lower postprandial blood
glucose concentration than
SF.Administration of oral DSF
and SF 60.93 ± 11.71
Pohl et al. [29] Germany 12 weeks
Randomized, double-blind,
controlled, multi-centre trial. n = 78
Median (Range)
DSF contained 37% energy as
CHO, 45% as fat, 18% as
protein, SF contained 52%
energy as CHO, 30% of
energy as total fat and 18% as
protein. No data
DSF formula resulted in a
more effective glycaemia
control than SF, and was
comparable in safety.
Test group
(DSF): 71 (42–86) Continuous Feeding.
DSF significantly decreased
triglycerides compared with
SF, but differences were not
significant in relation to total
cholesterol, HDL and LDL
cholesterols.Control group
(SF): 72 (51–87)
Pohl et al. [30] Germany 84 days
Parallel design.
n = 97
Median (Range)
DSF contained 37% energy as
CHO, 45% as fat, 18% as
protein, SF contained 52%
energy as CHO, 30% of
energy as total fat and 18% as
protein. No data
Compared to SF, DSF
significantly lowered FBG
and improved glycaemic
control.
Stage two of a randomized,
prospective, double-blind,
controlled, multicentre,
parallel group study
DSF: 74 (44–91) Continuous Feeding.
There were no significant
differences between the two
groups with respect to TG,
TC, HDL and LDL
cholesterols.
SF: 69 (53–86)
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Table 3. Cont.
Citation Country Length ofStudy Study Type/Design
Sample
Size/Description Age (Years)
Type of Enteral
Formula/Feeding Method
Duration of
Diabetes
(Years)
Study Results/Conclusion
Craig et al. [31] USA–New York
State
3 months
Randomized, double-blind,
controlled, parallel group 3
months pilot trial.
n = 34
DSF: 82 ± 3
(range 52–94)
Per 1000 mL, DSF contained
1000 kcal, 41.8 g protein, 93. 7
g CHO, 55.7 g fat. SF
contained 1060 kcal, 44.4 g
protein, 151.7 CHO, 35.9 g fat.
Continuous or intermittent
feeding.
No data
DSF resulted in lower fasting
serum glucose and HbA1c
than SF.
80 ± 2 (range-SF:
52–100)
No significant differences
between the DSF and SF
groups with respect to LDL
cholesterol and TG 3 months
post intervention, but the
DSF group had significantly
higher level of HDL
cholesterol than the SF group.
Lansink et al.
[32] Netherlands 4 weeks
Randomized, controlled,
double-blind, parallel-group
study.
n = 44
Mean ± SD
DSF contained 1 kcal/mL, 47
Energy% CHO, 19 Energy%
protein, 34 Energy% fat and 2
g fibres/100 mL. The SF
contained 50 Energy% CHO,
16 Energy% protein, 34
Energy% fat and 1.5 g
fibres/100 mL.
Mean (Range)
DSF:
84 (18–216)
months
DSF significantly lowered
postprandial glucose
compared with SF.
DSF: 65.2 ± 7.4
SF: 64.2 ± 5.9 Bolus Feeding
SF: 66 (10–504)
months
Levels of TG, TC, HDL and
LDL cholesterols were not
significantly different
between the two groups at
baseline and 4 weeks post
intervention.
Vaisman et al.
[33] No data 12 weeks
Randomized, controlled,
double-blind, parallel group
study.
n = 25
Total: 76.2 ±
12.8 years
DSF contained 100 kcal, 45
Energy% CHO, 38 Energy%
fat, 17 Energy% protein and
1.5 g/100 kcal fibre. SF
contained 100 kcal, 55
Energy% CHO, 30 Energy%
fat, 15 Energy% protein, 2
g/100 kcal fibre.
Mean ± SD
The DSF significantly
reduced HbA1c compared to
SF. No significant effect was
found with respect to fasting
blood glucose.
DSF: 73.0 ± 14.7 Bolus, Continuous orintermittent feeding.
Total: 8.6 ± 7.6
years
DSF: 5.0 ± 4.9
DSF significantly increased
HDL cholesterol, but
differences were not
significant in relation to TG,
TC and LDL cholesterol
compared with SF.
SF: 79.2 ± 10.4
SF: 12.6 ± 8.4
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Table 3. Cont.
Citation Country Length ofStudy Study Type/Design
Sample
Size/Description Age (Years)
Type of Enteral
Formula/Feeding Method
Duration of
Diabetes
(Years)
Study Results/Conclusion
Alish et al. [34] USA
10 days
Randomized, double blind,
two treatment, crossover
design.
n = 12
Mean ± SEM
DSF had 1.2 kcal/mL, 114.5 g
CHO, 17 g/L fibre, 60 g/L
protein, 60 g/L fat. SF had 1.2
kcal/mL, 169.4 g CHO, 18 g/L
fibre, 55.5 g/L protein, 39.3
g/L fat. NS
Use of DSF produced lower
postprandial glycaemic and
insulinemic responses,
reduced glycaemic
variability, and resulted in
less hyperglycaemia, reduced
short acting insulin
requirements.
DSF (Postprandial response
protocol) vs. SF (Continuous
glucose monitoring).
Postprandial:
63.1 ± 1.9 Continuous Feeding.
Continuous
feed: 74.1 ± 4.0
Gulati et al. [35] India 8 months
Open-label, randomized,
crossover, pilot single centre
study.
n = 40 35–60 years
DSF administered was 55 g in
210 mL of water to make 250
mL at standard reconstitution
(1 kcal/mL) which can be
used as tube feed or oral
nutrition supplement. The SF
was isocaloric Meal.
No data
DSF demonstrated lower
blood glucose and insulin
post meal levels than SF.
Bolus Feeding
The level of HDL cholesterol
was significantly higher in
the DSF group compared
with the SF group after
intervention, but differences
were not significant in
relation to TG, TC and LDL
cholesterol.
Hofman et al.
[36] Netherlands 360 min
Randomized, double blind,
cross over study involving SF
(A), DSF with moderate
amount of carbohydrate and
MUFA (B) and Test feed with
low amount of carbohydrate
and high amount of fat (C)
n = 12 63 ± 9.4 years
DSF (45 Energy% CHO, 26
Energy% MUFA), SF (49
Energy% CHO, 21 Energy%
MUFA). Continuous Feeding.
No data
DSF showed significantly
lower glucose levels
compared with SF.
With respect to TG level, the
DSF B with a lower amount
of fat showed significantly
lower levels than test feed C.
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Table 3. Cont.
Citation Country Length ofStudy Study Type/Design
Sample
Size/Description Age (Years)
Type of Enteral
Formula/Feeding Method
Duration of
Diabetes
(Years)
Study Results/Conclusion
Lansink et al.
[37] Netherlands 8 h
Randomized, controlled,
double-blind cross-over
study
n = 24
Mean ± SD
The DSF had 1.5 kcal/mL,
high protein, a mixture of 6
different dietary fibre and
low GI CHO. SF was
isocaloric fibre containing
formula.
Median
(Minimum and
Maximum)
Administration of a new,
high-protein DSF during 4 h
of continuous feeding
resulted in lower glucose and
insulin levels compared with
a fiber-containing SF. DSF
may contribute to lower
glucose levels in these
patients.64.6 ± 10.7 Continuous Feeding. 76.5 months (13,303)
Mesejo et al.
[38]
Spain 2 years Prospective, open-label,
randomized study n = 157
Median
(Q1–Q3)
Per 100 mL, DSF had 100
kcal, 5.7 g protein, 8.2 g CHO,
4.4 g fat. SF had 100 kcal, 5/7
g protein, 10.93/15.3 g CHO,
3.79/5.3 g fat.
No data
DSFs lowered insulin
requirements, improved
glycaemic control and
reduced the risk of acquired
infections relative to SF.
New generation
DSF: 57 (43–70) Continuous Feeding.
Plasma levels of cholesterol
and TG were similar across
the three treatment groups.SF: 60 (45–71)
Control DSF: 58
(46–68)
Voss et al. [39] USA 240 min
Randomized cross
over-study
n = 48
Mean ± SEM
DSF had 1 kcal/mL, 47.8 g
CHO, 7.2 g fibre, 20.9 g
protein, 27.2 g fat. SF had
1.06 kcal/mL, 73 g CHO, 7.2 g
fibre, 20.9 g protein, 16.4 g fat.
DSF resulted in lower
postprandial blood glucose
response compared with SF.
Double-blinded with
three-treatments 56 ± 1.4 years Bolus Feeding
Vanschoonbeek
et al. [40] Netherlands
10 days Randomized, double-blind,
cross over study. n = 15
Mean ± SEM
Per 100 mL, DSF had 98 kcal,
1.44 g fibre and 5.44/50
(g/energy%) of fat. SF had
100 kcal, 1.4 g of fibre, 3.4/30
(g/energy%) of fat.),
Mean ± SEM
DSF rich in lowly digestible
carbohydrate sources can be
equally effective in lowering
the postprandial blood
glucose response as
low-carbohydrate, high-fat
enteral formulas without
elevating the plasma
triglyceride response.63 ± 1 years Bolus Feeding 9 ± 2 years
Abbreviations: NS (Not stated); DSF (Diabetes Specific Formula); CHO (Carbohydrate); FOS (Fructo-oligosaccharide); GI (Glycaemic Index); HbA1c (Glycated haemoglobin); SF (Standard
Formula); LDL (low density lipoprotein) Cholesterol; HDL (high density lipoprotein)Cholesterol; MUFA (mono-unsaturated fatty acid); FBG (fasting blood glucose); TC (total cholesterol);
TG (triglycerides); T2DM (type 2 diabetes mellitus).
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Table 4. Blood glucose parameters among individuals with diabetes (Meta-analysis Data Extraction Table).
Study
Reference Interventions
Pre-and Post
Intervention
Fasting Blood
Glucose
mmol/L Mean
± SD/Median
(Quartiles)
Glycated
Haemoglobin
% Mean ±
SD/Median
(Quartiles)
Total
Cholesterol
mmol/L Mean
± SD/Median
(Quartiles)
LDL
Cholesterol
mmol/L Mean
± SD/Median
(Quartiles)
HDL
Cholesterol
mmol/L Mean
± SD/Median
(Quartiles)
Triglycerides
mmol/L Mean
± SD/Median
(Quartiles)
Pohl. et al. [29] DSF, n = 39
Change from
baseline
** ∆−1.59 (−3.38
to −0.06)
** ∆−0.8 (−1.5 to
−0.5)
** ∆−0.37 (−1.00
to 0.56)
** ∆−0.28 (−1.46
to 0.53)
** ∆0.08 (−0.06
to 0.28)
** ∆−0.37 (−0.36
to 0.38)
SF, n = 39 Change frombaseline
** ∆−0.08 (−1.34
to 0.79)
** ∆0.0 (−0.4 to
0.3)
** ∆−0.23 (−1.22
to 0.46)
** ∆−0.52 (−1.48
to 0.04)
** ∆0.05 (−0.10
to 0.32)
** ∆0.203 (−0.07
to 0.84)
Pohl et al. [30] DSF, n = 48
Change from
baseline
** ∆−2.17
(−2.55/−1.33)
** ∆−1.30
(−2.60/−0.10)
** ∆0.30
(−1.22/1.06)
** ∆0.27
(−0.71/1.40
** ∆0.03
(−0.26/0.4)
** ∆−0.45
(−1.65/0.27)
SF, n = 49 Change frombaseline
** ∆−0.67
(−0.90/−0.10)
** ∆−1.20
(−2.35/−0.55)
** ∆0.21
(−1.02/0.48)
** ∆−0.33
(−1.03/0.56)
** ∆0.00
(−0.22/0.28)
** ∆−0.70
(−1.50/1.73)
Craig et al. [31]
DSF, n = 14 Baseline * 7.3 ± 0.4 * 6.9 ± 0.3 * 4.16 ± 0.31 * 2.66 ± 0.23 * 1.01 ± 0.05 * 0.97 ± 0.13
Final 6.7 ± 0.7 6.5 ± 0.4 3.96 ± 0.31 2.51 ± 0.28 0.98 ± 0.05 0.91 ± 0.17g/L
SF, n = 13 Baseline * 6.9 ± 0.6 * 6.9 ± 0.5 * 4.21 ± 0.18 * 2.69 ± 0.15 * 0.98 ± 0.05 * 0.9 ± 0.07
Final 8.3 ± 1.7 6.9 ± 0.14 3.96 ± 0.23 2.53 ± 0.21 0.83 ± 0.05 1.06 ± 0.12 g/L
Lansink et al.
[32]
DSF, n = 21 Baseline * 8.32 ± 0.33 No data No data No data No data No dataFinal 8.13 ± 0.33
SF, n = 22 Baseline * 7.73 ± 0.22 No data No data No data No data No dataFinal 8.22 ± 0.26
Vaisman et al.
[33]
DSF, n = 12 Baseline No data
*** 6.9 ± 0.3
No data No data
*** 1.04 ± 0.08
No dataFinal 6.2 ± 0.4 1.23 ± 0.10
SF, n = 13 Baseline No data
*** 7.9 ± 0.3
No data No data
*** 1.06 ± 0.08
No dataFinal 8.7 ± 0.4 0.94 ± 0.09
Abbreviations: NS (Not stated); SD (Standard deviation); SEM (Standard Error of Mean); ∆ (Change from baseline) * Mean ± SD; ** Median (Quartiles); *** Mean ± SEM.
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3.2. Assessment of Risk of Bias in Included Studies
Figure 2 shows the risk of bias summary of the various studies included in the meta-analysis.
All the studies demonstrated low risk of bias in all the areas, except with respect to incomplete outcome
data (attrition bias) where two studies [29,33] showed high risk of bias.
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Based on the findings of the review and the meta-analysis, two distinct areas were evident: the
effect of DSF on blood glucose parameters and the effect of DSF on lipid profile.
The effect DSF on blood glucose parameters:
All the fourteen studies included in the systematic review showed that DSF was effective in
lowering blood glucose parameters in patients with type 2 diabetes compared with SF. In particular,
DSF improved glycaemic control and lowered insulin requirements [18,29,31,35–39]. It provided better
clinical outcomes, including reducing the risk of acquired infections and pressure ulcer, reduced body
weight and was safer compared to SF [29,31,32]. In addition, the use of DSF was shown to be effective
in lowering postprandial blood glucose levels compared to SF [20,32,34,40].
Pohl et al. [30] observed that long-term tube feeding with a DSF significantly lowered fasting
blood glucose and improved glycaemic control. Similarly, Vaisman et al. [33] reported that DSF
significantly improved longer-term glycaemic control in diabetic patients compared to SF. The results
of the meta-analysis confirmed the findings of the systematic review. With respect to the fasting blood
glucose, it was significantly lower (p = 0.01) in the DSF group compared to SF, with a mean difference
of −1.15 (95% CI −2.07, −0.23) (Figure 3). However, in relation to the sensitivity analysis, there were no
significant differences (p > 0.05) between the two groups with the removal of Pohl et al. [29,30] studies.
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The glycated haemoglobin was significantly lower (p = 0.005) in the DSF group compared to the
SF group following meta-analysis (Figure 4) and sensitivity analysis.
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3.3. The Effect of DSF on Lipid Profile
Based on the systematic review, the outcomes of the studies selected to evaluate the effect of DSF
on lipid profile w re variable. Craig et al. [31] did not find significant iff rences with respect to LDL
cholesterol and triglyce de between the DSF and he SF roups, but differ nces w re significantly
higher (p < 0.05) in the DSF group in relation to HDL cholesterol. In two other studi s [33,35], the level
of HDL cholesterol was significantly higher (p < 0.05) in th DSF group c mpared with the SF group
after intervention, but differences were not significant (p > 0.05) in relation to triglycerides, total
cholesterol and LDL cholesterols. Differences between DSF and SF were also not significant (p > 0.05) in
terms of triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol in other studies [30,32,38].
In contrast, Pohl et al. [29] r ported that there was a significant difference (p < 0.05) between th DSF
group and the SF group with respect to triglycerides, but differences were not sig ificant (p > 0.05) in
relation to total cholesterol, HDL and LDL cholesterol. Other studies [36,40] have also shown that DSF
is effective in controlling plasma trig yceride.
Following meta-analysis, no significa t iffere ces ( . ) ere f et een the SF and SF
groups with respect to total cholesterol, LDL cholesterol and triglyceride (Figures 5–7). o ever, the
DSF group had a significantly higher level (p = 0.04) of HDL cholesterol compared to the SF group
after the intervention, with a mean difference of 0.09 (95% CI, 0.00, 0.18) (Figure 8). The results of the
sensitivity test for HDL cholesterol demonstrated no significant differences (p > 0.05) between the
two groups when the Craig et al. [31] and Vaisman et al. [33] studies were removed from the analysis.
In a dition, the sensitivity analysis showed no significant differences (p > 0.05) between the two groups
with respect to total cholesterol and triglyceride, hile si ifi t iff ( 0.05) ere observed in
relation t LD cholest rol when the Craig et al. [31] study was removed.
Nutrients 2019, 11, 1905 14 of 18
Nutrients 2019, 11, x FOR PEER REVIEW 14 of 18 
 
 
Figure 5. The effect of DSF on total cholesterol (mmol/L). 
 
Figure 6. The effect of DSF on LDL cholesterol (mmol/L). 
 
Figure 7. The effect of DSF on Triglycerides (mmol/L). 
 
Figure 8. The effect of DSF on HDL cholesterol (mmol/L). 
4. Discussion 
The findings of the systematic review and meta-analysis revealed that DSF was effective in 
lowering blood glucose (fasting blood glucose and glycated haemoglobin) compared with SF in 
patients with type 2 diabetes. However, the sensitivity analysis for the fasting blood glucose did not 
demonstrate a significant difference (p > 0.05) with the removal of the Pohl et al. [29,30] studies. In 
addition, there were no significant differences (p > 0.05) between the DSF and SF groups with respect 
to total cholesterol, LDL cholesterol and triglyceride (although a few studies reported significant 
differences with respect to triglyceride). Differences in the outcomes of studies in the systematic 
review were observed with respect to the effect of DSF on HDL cholesterol and the meta-analysis 
also showed significantly higher levels for the DSF group compared with the SF group. The high level 
of heterogeneity in the studies included in the meta-analyses may explain why the results of the meta-
analysis and the sensitivity analysis were not consistent with respect to HDL cholesterol and fasting 
blood glucose. 
Figure 5. The effect of DSF on total cholesterol (mmol/L).
Nutrients 2019, 11, x FOR PEER REVIEW 14 of 18 
 
 
Figure 5. The effect of DSF on total cholesterol (mmol/L). 
 
Figure 6. The effect of DSF on LDL cholesterol (mmol/L). 
 
Figure 7. The effect of DSF on Triglycerides (mmol/L). 
 
Figure 8. The effect of DSF on HDL cholesterol (mmol/L). 
4. Discussion 
The findings of the systematic review and meta-analysis revealed that DSF was effective in 
lowering blood glucose (fa ing blood glucose and glyc ted haemoglobin) compared with SF
pati nts with type 2 diabete . However, the sensitivity analysis for the fast g blood glucose did not
demon trate a signific nt differenc  (p > 0.05) w h the removal of the Pohl et al. [29,30] stu es. In
addition, th re were no significant differences (p > 0.05) b tween the DSF and SF groups wi h respect
to total cholesterol, LDL cholesterol and triglyceride (although a few stu ies reported significan
differen es wi h respect to triglyceride). D fferences in e outcomes of studies in he ystem tic
review were observed with respe t to the e ct of DSF on HDL cholesterol and the meta-analys s
also sho d significantly higher l vels for the DSF group compared with he SF group. The high level
of heterog ne ty in the stud es included in meta-analyses m y explain why the results of the meta-
analysis and the sensitivity analysis were not consistent with respect to HDL c olesterol and fasting 
blood glucose. 
Figure 6. The effect of DSF on LDL cholesterol (mmol/L).
Nutrients 2019, 11, x FOR PEER REVIEW 14 of 18 
 
 
Figure 5. The effect of DSF on total cholesterol (mmol/L). 
 
Figure 6. The effect of DSF on LDL cholesterol (mmol/L). 
 
Figure 7. The effect of DSF on Triglycerides (mmol/L). 
 
Figure 8. The effect of DSF on HDL cholesterol (mmol/L). 
4. Discussion 
The findings of the systematic review and meta-analysis revealed that DSF was effective in 
lowering blood glucose (fasting blood glucose and glycated haemoglobin) compared with SF in 
patients with type 2 diabetes. However, the sensitivity analysis for the fasting blood glucose did not 
demonstrate a significant difference (p > 0.05) with the removal of the Pohl et al. [29,30] studies. In 
addition, there were no significant differences (p > 0.05) between the DSF and SF groups with respect 
to total cholesterol, LDL cholesterol and triglyceride (although a few studies reported significant 
differences with respect to triglyceride). Differences in the outcomes of studies in the systematic 
review were observed with respect to the effect of DSF on HDL cholesterol and the meta-analysis 
also showed significantly higher levels for the DSF group compared with the SF group. The high level 
of heterogeneity in the studies included in the meta-analyses may explain why the results of the meta-
analysis and the sensitivity analysis were not consistent with respect to HDL cholesterol and fasting 
blood glucose. 
Figure 7. The effect of DSF on Triglycerides (mmol/L).
Nutrients 2019, 11, x FOR PEER REVIEW 14 of 18 
 
 
Figure 5. The effect of DSF on total cholesterol (mmol/L). 
 
Figure 6. The effect of DSF on LDL cholesterol (mmol/L). 
 
Figure 7. The effect of DSF on Triglycerides (mmol/L). 
 
Figure 8. The effect of DSF on HDL cholesterol (mmol/L). 
4. Discussion 
The findings of the systematic review and meta-analysis revealed that DSF was effective in 
lowering blood glucose (fasting blood glucose and glycated haemoglobin) compared with SF in 
patients with type 2 diabetes. However, the sensitivity analysis for the fasting blood glucose did not 
demonstrate a significant difference (p > 0.05) with the removal of the Pohl et al. [29,30] studies. In 
addition, there were no significant differences (p > 0.05) between the DSF and SF groups with respect 
to total cholesterol, LDL cholesterol and triglyceride (although a few studies reported significant 
differences with respect to triglyceride). Differences in the outcomes of studies in the systematic 
review were observed with respect to the effect of DSF on HDL cholesterol and the meta-analysis 
also showed significantly higher levels for the DSF group compared with the SF group. The high level 
of heterogeneity in the studies included in the meta-analyses ay explain why the results of the meta-
analysis and the sensitivity analysis were not consistent with respect to HDL cholesterol and fasting 
blood glucose. 
Figure 8. The effect of DSF on HDL cholesterol (mmol/L).
4. Discussion
The findings of the syst matic review and meta-analysis revea ed that DSF was effective in
lowering blood glucose (fasting blood glucose and glycated haemoglobin) compared with SF in
patients with type 2 diabetes. However, the sensitivity analysis for the fasting blood glucose did
not d monstrate a significan difference (p > 0.05) with the remo al of the P hl et al. [29,30] studies.
In ddition, ere were no sign ficant differ nces (p > 0.05) b tween DSF and SF g o ps with respect
to total chol s erol, LDL chol sterol and triglycer d (although a few studies reported significant
differe ces with respect to triglyceride). Differences in the outcomes of studies in the systematic
review were observed with respect to the effect of DSF on HDL cholesterol and the meta-analysis
also showed significantly higher levels for the SF group compared with the SF group. The high
level of heterogeneity in t e studies included in the meta-analyses may explain why the results of the
meta-analysis and the sensitivity analysis were not consistent with respect to HDL cholesterol and
fasting blood glucose.
The presence of low glycaemic index (GI) carbohydrate in the form of isomaltulose, the lower
amount of carbohydrate and the higher protein content in the DSF may have contributed to the
findings of this review [37]. In addition, the presence of mono-unsaturated fatty acids (MUFA) and the
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different amounts and types of fibre in the DSF compared with SF may be responsible for the observed
differences in the fasting blood glucose, glycated haemoglobin and lipid profiles in both groups [18,41].
DSFs are usually higher in fat (40–50% of energy with a significant portion of MUFA) and have a lower
carbohydrate level (30–40% of energy) and about 15% of energy is derived from fructose and soluble
fibre [20]. DSFs contain carbohydrates with low GI such as non-hydrolysed starches, disaccharides,
fibre and fructose in varying amounts which are aimed at controlling postprandial glucose [17–20].
In contrast, SFs are high in carbohydrate (about 50%) and have low–moderate levels of lipids (about
30%) and do not contain dietetic fibre [17]. A study by Hofman et al. [42] demonstrated that, in 12
enteral formulas examined, the GI ranged from 12 for DSFs up to 61 for SFs. The GI of food is a measure
of how quickly the food is digested and the glucose reaches the blood stream [22,43]. Foods with high
GI rapidly increase blood glucose and insulin responses after consumption [43,44]. The results from
meta-analysis showed that the intake of a low GI diet was associated with reductions in blood glucose
parameters [35,43]. In addition, high soluble fibre-containing foods can improve glycaemic control
partly due to delayed absorption [36].
Therefore, DSFs may improve glycaemic control through delay in gastric emptying, delayed intestinal
absorption of carbohydrate and lower glycaemic response [20]. In the study by Alish et al. [34], the
blend of DSF was made up of low glycaemic and slowly digestible carbohydrates, resistant maltodextrin,
isomaltulose, sucromalt and prebiotic fibres, including fructo-oligosaccharides. These constituents
collectively produce a slow and consistent release of glucose into the blood stream [34]. Isomaltulose is a
naturally occurring low GI slowly digestible carbohydrate [18]. The slower hydrolysation of isomaltulose
during digestion may be responsible for the slower rise in blood glucose in patients with diabetes on
DSF [18]. In addition, the higher protein content of the DSF may have contributed to the lowering of
blood glucose parameters by delaying gastric emptying [18].
The use of high fat content, including MUFA, in the DSF may slow the transit time in the
gastrointestinal tract and slow the absorption of sugars which could help improve glycaemic control [35,41].
Diets that are high in MUFA have been shown to increase HDL cholesterol and reduce other components
of the lipid profiles [35,41]. HDL cholesterol is useful for reducing the risk of cardiovascular disease [35].
The result of the meta-analysis of the current review confirmed the positive role of DSF in increasing
HDL cholesterol. However, the sensitivity tests did not demonstrate consistency in terms of the effect of
DSF on HDL cholesterol, which could explain why researchers may be reluctant to recommend the use
of high fat content in DSF due to the risk of alterations in lipid profiles [41]. This may also be due to the
fact that there have been differences in the outcomes of studies on the effect of DSF on lipid profile [41].
5. Limitation
The limitation of this review was that only five studies were included in the meta-analysis.
In particular, there were fewer studies included for lipid outcomes (three for several parameters) and
there was substantial variability in the studies. Therefore, the differences between the meta-analysis and
the sensitivity analysis in some of the parameters suggest that those results were not quite consistent,
which may be due to the high level of heterogeneity of the studies. Therefore, more studies are needed
to address this problem.
6. Conclusions
The results provide evidence to suggest that DSF is effective in controlling fasting blood glucose
and glycated haemoglobin. In addition, DSF was effective in increasing HDL cholesterol but had
no significant effect on other lipid parameters. However, our confidence in these findings would
be increased by additional data from further studies. Additional research would also provide the
opportunity to refine our understanding of the effect of DSF on cardiometabolic parameters.
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